An increasing number of studies have revealed that EZH2 is abnormally expressed in numerous tumors, including liver cancer, gastric cancer, and breast cancer, and correlates with tumor progression, metastasis, and drug resistance in prostate cancer cells [11,12,13]. The gene discussed is EZH2; the disease is neoplasm.